Mark A. Goldberg's Insider Trades & SAST Disclosures
Mark A. Goldberg's most recent trade in Blueprint Medicines Corp was a trade of 4,570 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark A. Goldberg.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 18,254 (0%) | 0% | 0 | Common Stock | |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 29 Mar 2024 | 4,584 | 24,828 (0%) | 0% | 3 | 13,752 | Common Stock | |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 29 Dec 2023 | 5,827 | 20,244 (0%) | 0% | 2.4 | 13,752 | Common stock | |
| Immunogen, Inc. | Alan Goldberg Mark | Director | Grant, award, or other acquisition of securities at price $ 29.65 per share. | 29 Dec 2023 | 569 | 60,720 (0%) | 0% | 29.7 | 16,871 | Common Stock |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 30 Sep 2023 | 9,167 | 14,417 (0%) | 0% | 1.5 | 13,751 | Common stock | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 18.87 per share. | 30 Jun 2023 | 894 | 59,088 (0%) | 0% | 18.9 | 16,870 | Common Stock |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 16,012 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 19,597 | 19,597 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 13,090 | 13,090 | - | - | Restricted Stock Unit | |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 3.84 per share. | 31 Mar 2023 | 4,394 | 58,194 (0%) | 0% | 3.8 | 16,873 | Common Stock |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 3,402 | 160,350 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,530 | 156,948 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 3,750 | 153,418 | - | - | Deferred Share Unit | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 2,600 | 13,412 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 149,668 | - | - | Deferred Share Unit | |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 3,545 | 134,668 | - | - | Deferred Share Unit | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Purchase of securities on an exchange or from another person at price $ 59.98 per share. | 03 Mar 2022 | 5,000 | 10,812 (0%) | 0% | 60.0 | 299,900 | Common Stock |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 2,380 | 129,304 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 2,048 | 126,924 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,000 | 124,876 | - | - | Deferred Share Unit | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock | |
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | ||
| GlycoMimetics Inc | Mark Alan Goldberg | Director | 18 May 2021 | 5,250 | 5,250 (0%) | 0% | 0 | Common Stock | ||
| Immunogen, Inc. | Mark Alan Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 1,666 | 109,876 | - | - | Deferred Share Unit | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Dec 2020 | 5,455 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 125.00 per share. | 24 Dec 2020 | 5,455 | 3,562 (0%) | 0% | 125 | 681,875 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.15 per share. | 24 Dec 2020 | 5,455 | 9,017 (0%) | 0% | 28.1 | 153,558 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.15 per share. | 18 Dec 2020 | 5,454 | 9,016 (0%) | 0% | 28.1 | 153,530 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 5,454 | 5,455 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 18 Dec 2020 | 5,454 | 3,562 (0%) | 0% | 120 | 654,480 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 115.00 per share. | 11 Dec 2020 | 5,455 | 3,562 (0%) | 0% | 115 | 627,325 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2020 | 5,455 | 10,909 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.15 per share. | 11 Dec 2020 | 5,455 | 9,017 (0%) | 0% | 28.1 | 153,558 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.15 per share. | 01 Dec 2020 | 5,454 | 9,016 (0%) | 0% | 28.1 | 153,530 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 5,454 | 16,364 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 01 Dec 2020 | 5,454 | 3,562 (0%) | 0% | 110 | 599,940 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 105.00 per share. | 19 Oct 2020 | 5,455 | 3,562 (0%) | 0% | 105 | 572,775 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.53 per share. | 19 Oct 2020 | 5,455 | 9,017 (0%) | 0% | 19.5 | 106,536 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2020 | 5,455 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 Oct 2020 | 5,454 | 3,562 (0%) | 0% | 100 | 545,400 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.53 per share. | 07 Oct 2020 | 5,454 | 9,016 (0%) | 0% | 19.5 | 106,517 | Common Stock |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2020 | 5,454 | 5,455 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 3,750 | 106,117 | - | - | Deferred Share Unit | |
| Immunogen, Inc. | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 2,934 | 102,367 | - | - | Deferred Share Unit | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 2,250 | 3,562 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 1,312 (0%) | 0% | - | Common Stock | |
| Blueprint Medicines Corp | Mark A. Goldberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 0 | - | - | Restricted Stock Units | |
| Immunogen, Inc. | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 17,000 | 99,433 | - | - | Deferred Share Unit | |
| GlycoMimetics Inc | Mark A. Goldberg | Director | 22 May 2020 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Immunogen, Inc. | Mark A. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 3,958 | 82,433 | - | - | Deferred Share Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges